Literature DB >> 3806614

1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.

B Bonnaud, H Cousse, G Mouzin, M Briley, A Stenger, F Fauran, J P Couzinier.   

Abstract

A series of 1-aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives were synthesized and evaluated as potential antidepressants. Compounds with the Z configuration were synthesized from 1-aryl-2-oxo-3-oxabicyclo[3.1.0]hexane and those with the E configuration from (E)-1-phenyl-2-(hydroxymethyl)cyclopropanecarboxylic acid. The compounds were evaluated in animal tests designed to reveal potential antidepressant activity and the existence of undesirable side effects. Several derivatives were more active than imipramine and desipramine. On the basis of its activity in pharmacological animal tests of antidepressant activity and its potential lack of side effects, 1-phenyl-1-[(diethylamino)carbonyl]-2- (aminomethyl)cyclopropane hydrochloride, midalcipran (INN), was selected for further development. This compound is currently in phase III clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3806614     DOI: 10.1021/jm00385a013

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

Review 1.  Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

2.  Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant milnacipran.

Authors:  C Palmier; C Puozzo; T Lenehan; M Briley
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants.

Authors:  Christian Puozzo; Simone Lens; Christian Reh; Karl Michaelis; Dominique Rosillon; Xavier Deroubaix; Dominique Deprez
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Improved cyclopropanation activity of histidine-ligated cytochrome P450 enables the enantioselective formal synthesis of levomilnacipran.

Authors:  Z Jane Wang; Hans Renata; Nicole E Peck; Christopher C Farwell; Pedro S Coelho; Frances H Arnold
Journal:  Angew Chem Int Ed Engl       Date:  2014-05-06       Impact factor: 15.336

Review 5.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

Review 6.  Milnacipran. A review of its use in depression.

Authors:  C M Spencer; M I Wilde
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.